Headline : Zynyz receives FDA accelerated approval for treatment of Merkel Cell Carcinoma

Read more from the original article on here at www.healthcaremea.com.

---

No. of Paragraph 40

USA — Incyte’s Zynyz (retifanlimab-dlwr) has received accelerated approval from the FDA for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults.

MCC is a rare type of skin cancer that grows rapidly and is often accompanied by a high incidence of metastasis, resulting in poor prognoses.

Although it is about 40 times rarer than melanoma, incidence rates are increasing, particularly among older adults, according to the Skin Cancer Foundation.

While the five-year overall survival rate is only 14% for patients with MCC with distant metastatic disease, incidence rates are rapidly increasing, particularly in adults over the age of 65, with less than 1 in 100,000 people in the United States affected by MCC.

Read more from the original article on here at www.healthcaremea.com.

Related Headlines : Zynyz receives FDA accelerated approval for treatment of Merkel Cell Carcinoma (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.